In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non-small-cell lung cancer by Huang,  T. H. et al.
J Cell Mol Med. 2019;00:1–12.	 	 	 | 	1wileyonlinelibrary.com/journal/jcmm
 
Received:	27	March	2019  |  Revised:	15	July	2019  |  Accepted:	23	July	2019
DOI: 10.1111/jcmm.14689  
O R I G I N A L  A R T I C L E
In silico identification of thiostrepton as an inhibitor of cancer 
stem cell growth and an enhancer for chemotherapy in non–
small‐cell lung cancer
Tse‐Hung Huang1,2,3,4,5 |   Alexander T. H. Wu6 |   Tai‐Shan Cheng7 |   Kuan‐Ting Lin8 |   
Chia‐Jou Lai7 |   Hao‐Wen Hsieh9 |   Peter Mu‐Hsin Chang10,11 |   Cheng‐Wen Wu9,12 |   Chi‐








































disease	progression.	 Identifying	an	effective	anti‐CSC	agent	may	 lead	 to	 improved	
disease	control.	We	used	CSC‐associated	gene	signatures	to	identify	drug	candidates	
that	may	 inhibit	CSC	growth	by	 reversing	 the	CSC	gene	signature.	Thiostrepton,	a	
natural	 cyclic	 oligopeptide	 antibiotic,	was	 the	 top‐ranked	 candidate.	 In	 non–small‐
cell	 lung	 cancer	 (NSCLC)	 cells,	 thiostrepton	 inhibited	 CSC	 growth	 in	 vitro	 and	 re‐
duced	protein	expression	of	cancer	stemness	markers,	including	CD133,	Nanog	and	
Oct4A.	In	addition,	metastasis‐associated	Src	tyrosine	kinase	signalling,	cell	migration	
and	 epithelial‐to‐mesenchymal	 transition	 (EMT)	were	 all	 inhibited	 by	 thiostrepton.	
Mechanistically,	thiostrepton	treatment	led	to	elevated	levels	of	tumour	suppressor	
miR‐98.	Thiostrepton	combined	with	gemcitabine	synergistically	suppressed	NSCLC	













The	 five‐year	 survival	 rate	 is	 approximately	18%	 for	patients	with	
lung	cancer	and	3.9%	for	those	with	advanced	stages2	of	the	disease,	







chemotherapy	 eventually	 encounter	 drug	 resistance	 and	 disease	
progression.9,10	 Alternative	 therapeutic	 strategies	 are	 urgently	
needed.
Cancer	stem	cells	(CSCs)	play	an	important	role	in	cancer	recur‐













information	 for	 a	 huge	 number	 of	 drugs.20	 The	Connectivity	Map	
(CMap,	 http://www.broad.mit.edu/cmap/),21	 which	 stores	 expres‐
sion	profiles	 of	 diseases,	 genes	 and	 chemicals,	 provides	 a	 tool	 for	
making	 inferences	based	on	a	query	 and	 the	 internal	profiles.	We	
hypothesized	that	drugs	with	 the	ability	 to	 reverse	the	expression	
of	CSC‐like	gene	signatures	may	inhibit	CSC	growth	and	could	prove	
beneficial	in	the	treatment	of	lung	cancer.	We	tested	the	top‐ranked	





thiopeptide	 family	 of	 highly	modified	macrocyclic	 peptides,	which	
are	 produced	 as	 secondary	 metabolites	 by	 actinomycetes	 of	 the	
genus	Streptomyces.22	Thiostrepton	interacts	directly	with	forkhead	
box	M1	 (FOXM1)	and	 inhibits	binding	with	genomic	 target	sites.23 
Thiostrepton	also	 inhibits	growth	and	 induces	apoptosis	 in	human	
cancer	 cells	 by	 inhibiting	 FOXM1	 expression.24	 Based	 on	 CMap	
analysis,	we	identified	thiostrepton	as	a	candidate	to	be	an	anti‐CSC	






2  | MATERIAL S AND METHODS
2.1 | Cell lines and chemicals
















Gene	 expression	 profiles	were	 obtained	 from	 cancer	 cells	 treated	
with	 perturbagens,	 including	 small	 molecules	 and	 Chinese	 herbal	
medicines,	 in	 triplicate	 for	 6	 hours,	 followed	 by	 L1000	 expres‐
sion	profiling21,27	by	Genometry	 Inc	 In	brief,	cells	were	 lysed	after	
6	hours	of	treatment	in	triplicate,	and	mRNA	transcripts	from	whole	
cell	 lysates	were	 rapidly	 captured	 by	 oligo‐dT.	 The	 cDNAs	 gener‐
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2.3 | Connectivity scoring by gene set enrichment 
analysis using CMap
Intensity	values	of	gene	expression	profiles	were	first	converted	
to	 robust	 z‐scores	 using	 the	 l1ktools	 downloaded	 from	 the	





connectivity	 score	 for	 each	 gene	 expression	 profile	 against	 the	
anti‐CSC	 or	 CSC	 gene	 signature.21	 The	 anti‐CSC	 gene	 signature	
was	 identified	using	GEO2R	for	differentially	expressed	genes	 in	
the	study	of,	 for	example,	 the	Gene	Expression	Omnibus28	 gene	
signature	GSE18150.29
The	 11	 641	 profiles	 in	 our	 collection	were	 ranked	 by	 connec‐
tivity	 scores	and	used	as	 the	 input	of	 the	 ranking	matrix	 for	gene	














ostrepton	was	 renewed	every	4	days.	Following	 the	 treatments,	
cells	 were	 washed	 with	 phosphate‐buffered	 saline	 (PBS),	 and	
the	colonies	were	fixed	 in	a	methanol‐acetic	acid	 fixing	solution	
with	 a	 ratio	of	3:1	 and	 stained	with	0.5%	crystal	 violet	 solution	
in	methanol.	After	carefully	 removing	 the	crystal	violet	 solution	
and	rinsing	with	 tap	water,	 the	colonies	were	counted	manually.	
Each	 experiment	 was	 performed	 independently,	 in	 triplicate,	 at	
least	twice.
2.5 | Cytotoxicity assay and drug 
combination analysis
Cells	were	seeded	 in	96‐well	plates	at	a	density	of	2000	cells	per	
well	 in	 triplicate.	 The	 cells	were	 treated	with	 indicated	 agents	 for	
48	hours	on	the	second	day	to	ensure	adequate	plating	efficiency	
and	cell	vitality.	Cells	were	treated	with	different	concentrations	of	











fined	 as	 the	 percentage	 of	 cells	 in	 the	 drug‐treated	wells	 relative	
to	the	cell	numbers	in	the	solvent‐only	control	(set	to	100%).	Each	
experiment	 was	 performed	 independently,	 in	 triplicate,	 at	 least	
twice,	and	the	cytotoxicity	was	presented	as	the	mean	±	standard	
deviation.
The	 synergy	 associated	 with	 inducing	 cytotoxicity	 among	 dif‐
ferent	 drug	 combinations	 was	 evaluated	 by	 analysis	 of	 the	 me‐
dian‐dose	effect	and	calculation	of	the	combination	index	(CI)	using	
commercially	 available	 software	 of	 Chou	 and	 Talalay	 software	






the	 transwell	with	200	μL	of	 serum‐free	medium,	 in	 the	presence	
of	the	vehicle	(DMSO)	or	thiostrepton	(5	μmol/L).	The	lower	cham‐








After	 treatments,	 cells	 were	 lysed	 in	 a	 lysis	 buffer.	 Total	 pro‐
tein	 contents	were	 isolated	 and	 subjected	 to	 SDS	 polyacrylamide	
gel	 electrophoresis	 and	 electro‐transferred	 onto	 polyvinylidene	
fluoride	 membranes	 (Millipore).	 Immunoblotting	 was	 performed	
using	 primary	 antibodies,	 including	 β‐catenin	 (Cell	 Signaling	
Technology),	c‐Myc	(Cell	Signaling	Technology),	CD44	(Cell	Signaling	
Technology),	 CD133	 (GeneTex),	 Oct‐4A	 (GeneTex),	 Sox2	 (Cell	
Signaling	 Technology),	 FOXM1	 (Abcam),	 E‐cadherin	 (Cell	 Signaling	
Technology),	 Src	 (Cell	 Signaling	 Technology),	 phosphorylated	
Src	 (Tyr416,	 Cell	 Signaling	 Technology),	 caspase‐8	 (Cell	 Signaling	
Technology),	caspase‐9	(Cell	Signaling	Technology),	caspase‐3	(Cell	
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Signaling	Technology)	and	cleaved	PARP	(Cell	Signaling	Technology).	









Briefly,	 a	 single	 cell	 suspension	 obtained	 from	 cell	 cultures	 was	
incubated	in	Aldefluor	assay	buffer	containing	an	ALDH	substrate	
(bodipy‐aminoacetaldehyde,	 BAAA)	 for	 50	 minutes	 at	 37°C.	 As	
a	 negative	 control,	 a	 fraction	 of	 cells	 from	 each	 sample	was	 in‐
cubated	 under	 identical	 conditions	 in	 the	 presence	 of	 an	 ALDH	
inhibitor	(diethylaminobenzaldehyde,	DEAB).	Flow	cytometry	was	
used	to	detect	the	ALDH‐positive	cell	population.
A	 tumour	 sphere	 formation	 assay	was	 carried	 out	 to	 evaluate	
cancer	stemness.	Lung	cancer	cells	were	seeded	in	6‐well	ultralow‐












vendor.	 Total	 RNA	was	 isolated,	 quantified	 and	 reverse	 transcribed	
into	cDNA.	The	primers	of	different	microRNAs	tested	in	this	study	for	
microRNA	quantitative	real‐time	PCR	assays	were	also	purchased	from	
QIAGEN.	 Up‐regulation	 and	 down‐regulation	 of	 miRNAs	 were	 per‐
formed	by	transfecting	cells	with	miRNA	precursors	or	anti‐miRNAs,	





2.10 | Examination of anti‐lung cancer effects 
mediated by thiostrepton in vivo
The	inhibitory	effect	of	thiostrepton	on	tumour	growth	was	evaluated	
by	using	a	mouse	subcutaneous	tumour	xenograft	model.	Human	lung	





kg,	 5	 days/wk,	 intraperitoneal	 injection)	 or	 a	 control	 group	 (DMSO	
vehicle).	Over	a	period	of	4	weeks,	 the	 tumour	sizes	 in	both	groups	
were	measured	weekly	with	standard	calipers.	The	in	vivo	tracking	of	
tumour	growth	was	then	determined	and	presented	as	the	fold	change	
in	 tumour	volume	over	 time.	All	 animal	experiments	were	approved	





3.1 | Identification of thiostrepton as a potential 
anti‐CSC agent using the Connectivity Map database
We	compared	20	different	published	data	sets	 (Table	S1)	and	em‐
ployed	 CSC‐related	 gene	 expression	 profiles	 as	 inputs	 to	 query	
11	 641	 L1000‐based	 gene	 expression	 profiles.	 Thiostrepton	 was	
identified	as	a	candidate	that	could	significantly	reverse	lung	cancer	
gene	 signatures	 (Figure	 1A).	As	 an	 example,	GSE18150	was	 origi‐
nally	generated	from	cells	treated	with	DZNep	by	disrupting	EZH2 
and	 impairing	 CSC	 self‐renewal.29	 Thiostrepton	 profiles,	 including	










When	 the	 anti‐CSC	 gene	 signature	 GSE18150	 determined	




more	 than	 1.3	 million	 gene	 expression	 profiles,	 thiostrepton	 was	
ranked	 as	 the	 22nd	 among	 drugs	 with	 positive	 similarity	 scores	
(score_best4	=	97.368).
The	human	normal	mammary	 stem	cell	 (hNMSC)	gene	expres‐
sion	 signature	 GSE18931,	 a	 CSC	 gene	 signature,	 can	 stratify	 bio‐
logical	and	molecular	features	in	tumours	(Table	S2).	The	degree	of	
cells	expressing	hNMSC	markers	may	reflect	the	CSC	content	of	a	
tumour.30	 L1000	 profiles	with	 a	 negative	 connectivity	 score	 (nor‐
malized	enrichment	score	=	−2.0146;	P‐value	<.0001;	false	discover	
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similarity	 scores.	This	 strong	 concordance	 across	different	pertur‐
bagen	databases	 indicated	 that	 thiostrepton	 is	 likely	 to	have	 anti‐
CSC	abilities.




idation	 was	 demonstrated	 by	 the	 up‐regulated	 expression	 of	 E‐
cadherin	 and	 down‐regulated	 expression	 of	 Slug	 and	 vimentin	 in	
thiostrepton‐treated	CL141	cells	(Figure	1D).	Moreover,	treatment	
with	 thiostrepton	not	only	distinctly	 reduced	FOXM1	expression	
but	 also	 reduced	 vimentin	 and	 Slug	 expression	 and	 inhibited	 Src	
and	 AKT	 activation	 in	 CL141	 cells	 in	 a	 dose‐dependent	 manner	
(Figure	1E).
3.2 | Thiostrepton suppresses NSCLC cell growth, 
clonogenicity and migration
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in	 the	 clonogenic	 assay	was	 approximately	 0.05	μmol/L,	which	
was	distinctly	lower	than	that	of	cytotoxic	effects	(Table	S3).	In	
addition,	 treatment	with	 thiostrepton	 significantly	 reduced	 the	















tumour	 spheres	 were	 enriched	 with	 ALDH1+	 cells	 (S:	 1.2%)	 com‐
pared	with	their	parental	counterparts	(P:	0.5%,	Figure	3A),	and	the	
relative	ALDH	activity	was	significantly	 increased	 (Figure	3B).	The	














3.4 | Thiostrepton and gemcitabine synergistically 
suppresses NSCLC tumour sphere formation
Thiostrepton	 in	 combination	 with	 gemcitabine,	 cisplatin,	 pem‐
etrexed	 or	 gefitinib	 reduced	NSCLC	 cell	 viabilities	 synergistically	











treated	with	 gemcitabine	 plus	 thiostrepton	 (Figure	 4C).	Apoptosis	
induced	 by	 gemcitabine	 plus	 thiostrepton	 was	 more	 significant	
compared	with	 that	 induced	by	gemcitabine	or	 thiostrepton	alone	
(Figure	4C).
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Furthermore,	the	combination	of	thiostrepton	and	gemcitabine	
suppressed	 expression	 of	 stemness	markers,	 such	 as	 Sox2,	 β‐cat‐
enin	 and	 EMT	 transcription	 factor	 Slug	 in	 both	CL141	 and	CL152	
cells	(Figure	4D),	indicating	that	the	combination	of	thiostrepton	and	
gemcitabine	suppresses	stemness‐	and	EMT‐related	profiles	in	both	
adenocarcinoma	 and	 squamous	 cell	 carcinoma	 cells.	 This	 finding	
suggests	thiostrepton	could	reduce	cancer	stem‐like	cell	populations	
and	decrease	the	risk	of	distant	metastasis.
We	 also	 characterized	 the	 combination	 treatment	 on	 CL141	
parental	cells	and	tumour	spheres.	Thiostrepton,	with	or	without	
gemcitabine,	 was	 able	 to	 suppress	 CD133	 expression,	 whereas	
gemcitabine	 treatment	 did	 not	 (Figure	 4E).	 Importantly,	 CL141	
spheres	 responded	 to	 a	 lower	 concentration	 of	 thiostrepton	
(1	µmol/L),	 as	 reflected	by	 significantly	 decreased	CD133	 levels	
(Figure	4E).	 In	 the	presence	of	 thiostrepton,	CL141	spheres	also	
responded	 to	 gemcitabine	 at	 a	 lower	 concentration	 and	 under‐
went	 apoptotic	 cell	 death	 as	 reflected	 by	 the	 elevated	 level	 of	
cleavage	of	PARP.
3.5 | Thiostrepton inhibits NSCLC 
tumorigenesis and decreases the proportion of CSC 
in vivo
NOD/SCID	 mice	 that	 received	 daily	 thiostrepton	 treatment	
(n	 =	5)	 exhibited	 a	 significantly	 slower	 tumour	 growth	 rate	 than	
mice	 receiving	 the	 vehicle	 treatment	 (n	 =	 5)	 at	 the	 fifth	 week,	
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as	 demonstrated	 by	 approximately	 2‐fold	 smaller	 in	 tumour	 size	
(Figure	5A).	The	body	weight	of	 the	mice	did	not	change	signifi‐
cantly	 during	 the	 treatment	 period	 (Figure	 5B).	 Photographs	 of	
harvested	 tumour	 samples	 showed	 that	 thiostrepton	 treatment	
significantly	 suppressed	 tumour	 growth	 compared	 with	 control	




3.6 | Thiostrepton treatment was associated with an 
increase in tumour suppressor miR‐98






a	 significantly	 higher	 level	 of	 intrinsic	 miR‐98	 than	 their	 sphere	
counterparts	 (Figure	6B).	 The	 level	 of	miR‐98	 rose	 in	 the	wake	of	
thiostrepton	 treatment	 in	 both	 CL141	 parental	 cells	 and	 spheres	
(Figure	6B).
By	 increasing	 miR‐98	 (mimic	 molecules)	 levels,	 Sox2,	 Oct‐4A	
and β‐catenin	 were	 suppressed	 in	 both	 CL141	 and	 CL152	 cells	
(Figure	6C).	This	was	similar	to	the	response	to	thiostrepton	treat‐
ment	 in	 CL141	 cells.	 Based	 on	 the	 decreased	 expression	 of	 Slug,	





verting	embryonic	 stem	cell‐like	gene	 signatures	 to	 those	of	 adult	
stem	cell	gene	signatures.	Through	in	vitro	and	in	vivo	experiments,	
we	demonstrated	 that	 thiostrepton	effectively	 inhibited	 lung	CSC	
growth	by	the	suppressing	cancer	stemness	and	expression	of	EMT	
genes.	A	combination	of	thiostrepton	and	gemcitabine	synergistically	
















In	 tumour	 sphere	assays,	 increased	EMT	potential	 and	expres‐
sion	 of	 CSC	markers	were	 showed	 in	NSCLC	 cells.	 This	 finding	 is	






nocarcinoma,	 thereby	 promoting	 cancer	metastasis.43	Knockdown	
FOXM1	significantly	suppressed	EMT	progression	as	well	as	tumour	
growth	 and	metastasis.43	 However,	 we	 demonstrated	 that	 thiost‐
repton	 treatment	 did	 not	 inhibit	 Snail	 expression	 but	 strongly	 in‐
hibited	Slug	expression	in	NSCLC	cells.	These	findings	indicate	that	
the	CD133/Src	axis,	in	addition	to	FOXM1,	is	a	potential	therapeutic	
target	 for	 thiostrepton.	 Thiostrepton	 treatment	 not	 only	 inhibited	
CSC	markers	including	CD133,	Oct‐4A	and	Sox2,	but	also	restored	





cell	 and	mesenchymal	 cell	 populations,	 the	ability	 to	 form	 tumour	
spheres	and	enhanced	drug	resistance.25	To	provide	further	support	
the	contention	 that	 thiostrepton	 is	a	potential	anti‐CSC	agent,	we	
utilized	a	cell	model	that	A549	cells	with	overexpression	of	Oct‐4A/
Nanog	 exhibits	 enhanced	 CSC	 characteristics	 and	 EMT	 potential.	














preventing	drug	 resistance.	Thiostrepton	 acted	 synergistically	with	
gemcitabine	to	inhibit	lung	cancer	cellular	viability	in	this	study.
The	 GSEA	 results	 of	 thiostrepton	 and	 thiostrepton	 plus	 gem‐


















to	 E‐type	 cells.35	 Chemotherapy	 combined	with	 thiostrepton	may	
therefore	be	an	alternative	regimen	to	improve	treatment	effective‐
ness	and	prolong	survival	in	patients	with	NSCLC.
Chemotherapy	 is	 still	 a	major	 treatment	 option	 for	 lung	 squa‐
mous	 cell	 carcinoma.	 Thiostrepton	 in	 combination	 with	 gemcit‐
abine	significantly	 inhibited	 lung	squamous	cell	carcinoma	growth.	




than	 in	CL152	 cells.	While	 gemcitabine	 treatment	 alone	 appeared	
to	suppress	Sox2	expression	more	significantly	 in	CL152	cells,	 the	







In	 this	 study,	 an	 increased	 level	 of	miR‐98	 (a	 tumour	 suppres‐
sor)	was	observed	 in	response	to	thiostrepton	treatment.	Because	




In	 conclusion,	 thiostrepton	 was	 identified	 as	 a	 potential	 CSC	
inhibitor	 for	 lung	 cancer	 using	 an	 integrative	 bioinformatics	 and	
pre‐clinical	 approach.	 In	 combination	 with	 chemotherapeutic	
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